{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.28","value":"3.5"},{"groupId":"OG001","spread":"11.08","value":"2.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"52"}],"units":"Participants"}],"title":"Week 4 CORE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.97","value":"2.4"},{"groupId":"OG001","spread":"12.11","value":"2.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"52"}],"units":"Participants"}],"title":"Week 8 CORE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.41","value":"3.0"},{"groupId":"OG001","spread":"11.50","value":"1.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"50"}],"units":"Participants"}],"title":"Week 12 CORE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.99","value":"3.3"},{"groupId":"OG001","spread":"15.33","value":"6.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"52"}],"units":"Participants"}],"title":"Week 16 CORE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.89","value":"3.5"},{"groupId":"OG001","spread":"16.02","value":"4.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"50"}],"units":"Participants"}],"title":"Week 20 CORE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.61","value":"3.0"},{"groupId":"OG001","spread":"17.77","value":"5.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"53"}],"units":"Participants"}],"title":"Week24 CORE"}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"54"}],"units":"Participants"}],"description":"Acromegaly Quality of Life questionnaire (AcroQoL) is a validated disease specific questionnaire. It contains 22 items divided into two scales: physical aspects (8 items) and psychological aspects (14 items) which is divided in two sub-scales: physical appearance and personal relationships of the patient (seven items each). The total score and sub-scores were calculated using the following formula: ((X -Y) / 4Y) x 100, X=sum of the scores for individual items (between 1 and 5 for each item), Y=number of individual items included in above sum (i.e. 22 for the total score, 8 for the physical sub-score, 14 for the psychological sub-score, 7 for the sub-score 'appearance' and 'personal relations'). The scoring of the questionnaire was performed as specified by the instrument developers. Total scores range from 0 to 100. Higher scores represent better quality of life. If more than 25% of items are not completed, results were considered invalid.","dispersionType":"Standard Deviation","groups":[{"description":"Supplied in blinded fashion as 20 and 40 mg powder in vials and 2 mL vehicle in ampoule (for reconstitution) for intramuscular administration every 28 days","id":"OG000","title":"Pasireotide LAR 40 mg"},{"description":"Supplied in blinded fashion as 20 and 40 mg powder in vials and 2 mL vehicle in ampoule (for reconstitution) for intramuscular administration every 28 days","id":"OG001","title":"Pasireotide LAR 60 mg"}],"paramType":"MEAN","populationDescription":"Available data available for analysis differed from visit to visit","reportingStatus":"POSTED","timeFrame":"CORE baseline up to approximately 24 weeks","title":"Change From Baseline in AcroQoL Total Scores for Patients Treated With Pasireotide LAR Alone or With Concomitant Medications Used to Treat Acromegaly for CORE Visits(Extension Full Analysis Set)","type":"SECONDARY","unitOfMeasure":"scores on a scale"}